We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor.
- Authors
Gil-Etayo, Francisco Javier; Garcinuño, Sara; Lalueza, Antonio; Díaz-Simón, Raquel; García-Reyne, Ana; Pleguezuelo, Daniel Enrique; Cabrera-Marante, Oscar; Rodriguez-Frias, Edgard Alfonso; Perez-Rivilla, Alfredo; Serrano, Manuel; Serrano, Antonio
- Abstract
Background: COVID-19 clinical features include a hypercoagulable state that resembles the antiphospholipid syndrome (APS), a disease characterized by thrombosis and presence of antiphospholipid antibodies (aPL). The relationship between aPL-presence and the appearance of thrombi as well as the transience or permanence of aPL in COVID-19 patients is not sufficiently clear. Methods: A group of 360 COVID-19 patients were followed-up for 6 months. Classic aPL, anti-B2GPI IgA, anti-phosphatidylserine/prothrombin IgG/M and anti-SARS-CoV-2 antibodies were determined at acute phase and >12 weeks later. The reference group included 143 healthy volunteers of the same age-range distribution. Results: aPL prevalence was similar in COVID-19 patients and the reference population. aPL presence in both determinations was significantly associated with thrombosis (OR: 2.33 and 3.71), strong agreement being found for classic aPL and anti-B2GPI IgA (Weighted kappa: 0.85–0.91). Thrombosis-associated aPL occurred a median of 17 days after hospital admission (IQR: 6–28) vs. 4 days for the rest (IQR: 3–7). Although anti-SARS-CoV-2 antibodies levels increased during convalescence, aPL hardly changed. Conclusions: Most COVID-19 patients would carry these aPL before the infection. At least two mechanisms could be behind thrombosis, early immune-dysregulation-mediated thrombosis after infection and belated-aPL-mediated thrombosis, with SARS-CoV-2 behaving as a second hit.
- Subjects
ANTIPHOSPHOLIPID syndrome; PHOSPHOLIPID antibodies; COVID-19; THROMBOSIS; IMMUNOGLOBULIN G; SARS-CoV-2
- Publication
Biomedicines, 2021, Vol 9, Issue 8, p899
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines9080899